Clinical Trials Directory

Trials / Completed

CompletedNCT05029427

Effect of Oat Beta Glucan in Managing Blood Pressure

Effect of Oat Beta Glucan in Managing Blood Pressure: a Randomized Cross-over Pilot Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
23 (actual)
Sponsor
University of Manitoba · Academic / Other
Sex
All
Age
40 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This is a randomized, double-blinded, cross-over pilot study comparing the effects of ingesting oats containing high molecular weight β-glucan in reducing blood pressure.

Detailed description

The pilot study will consist of 2 study periods: one treatment period and one control period. The treatment period will provide food products made from oats containing a total of 4 grams per day high molecular weight (HMW) oat β-glucan, whereas, the control period will provide food products made primarily from wheat with no β-glucan. The study will be located at the Chronic Disease Innovation Centre in Seven Oaks General Hospital, Winnipeg, Canada. The primary objective of this study is to investigate the effect of ingestion of HMW oat β-glucan on ambulatory blood pressure. Participants will be asked to wear an ambulatory blood pressure monitor for 24 hours per day for 3 consecutive days at the beginning and end of each treatment period. This device automatically measures blood pressure every 15-30 minutes during the day and 30 to 60 minutes during the evening. The study has been designed to be conducted virtually. Participants will consent to receive both treatment and control over two 4-week periods online. The participants will be randomized to different orders of treatment, with a 4 week wash out period in between.

Conditions

Interventions

TypeNameDescription
OTHERHigh molecular weight β-glucan oat cookiesTwo cookies that contains 4g beta glucan made from oats will be consumed per day.
OTHERControl wheat based cookiesTwo cookies that made from cream of wheat without beta glucan will be consumed per day.

Timeline

Start date
2021-11-28
Primary completion
2022-12-14
Completion
2022-12-23
First posted
2021-08-31
Last updated
2023-01-26

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT05029427. Inclusion in this directory is not an endorsement.